Dole plc Reports Fourth Quarter and Full Year 2022 Financial Results
Dole plc reported its financial results for the year ending December 31, 2022, highlighting a revenue of $9.2 billion and an Adjusted EBITDA of $337.7 million. Despite a 0.6% revenue decline from the previous year, revenue increased 5.0% on a like-for-like basis, boosted by price inflation. The company announced plans to sell its Fresh Vegetables division for approximately $293 million to enhance its financial position and focus on core operations. Dole targets an Adjusted EBITDA of $350 million for 2023, emphasizing growth potential through a diversified product portfolio and geographic presence.
- Revenue increased 5.0% on a like-for-like basis, driven by price inflation.
- Adjusted EBITDA rose 21.7% in Q4 and was $337.7 million for the full year.
- Plans to sell Fresh Vegetables division will strengthen financial position.
- Full year revenue decreased 0.6%, or $56.8 million, on a pro-forma basis.
- Adjusted EBITDA decreased 14.2% or $55.9 million compared to the prior year.
- Adjusted net income decreased by 34.9% to $92 million.
Highlights for the year ended
-
First full year of
Dole plc results post-acquisition - Good progress made on integration of legacy businesses and rebranding of European operations
- Launch of Dole Exotics and the "BeExotic" brand
- Released first Dole plc Sustainability Report, outlining medium to long-term sustainability goals
-
Post year end, announced the Agreement to sell our Fresh Vegetables division to Fresh Express, for gross proceeds of approximately
$293.0 million - Satisfactory full year financial performance delivered in a challenging operating environment
-
Full year revenue of
and Adjusted EBITDA1 of$9.2 billion , in-line with our latest guidance$337.7 million
Financial Highlights – Unaudited
|
Three Months Ended |
|
Year Ended |
|||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|
2021 Pro-forma2 |
|||||
|
|
|
|
|
|
|
|
|
|
|||||
|
( |
|||||||||||||
Revenue |
2,356 |
|
2,251 |
|
9,229 |
|
6,454 |
|
9,286 |
|||||
Net Income (Loss) |
13.3 |
|
|
(24.6 |
) |
|
111.7 |
|
|
16.8 |
|
|
177.6 |
|
Net Income (Loss) attributable to |
6.8 |
|
|
(29.3 |
) |
|
86.5 |
|
|
(7.2 |
) |
|
151.7 |
|
Diluted EPS |
0.07 |
|
|
(0.31 |
) |
|
0.91 |
|
|
(0.10 |
) |
|
1.60 |
|
Adjusted EBITDA1 |
74.4 |
|
|
61.1 |
|
|
337.7 |
|
|
290.1 |
|
|
393.6 |
|
Adjusted Net Income1 |
8.9 |
|
|
0.0 |
|
|
92.0 |
|
|
73.1 |
|
|
141.2 |
|
Adjusted Diluted EPS1 |
0.09 |
|
|
0.00 |
|
|
0.97 |
|
|
1.01 |
|
|
1.49 |
|
1 |
||
2 This press release contains pro-forma financial information. The unaudited pro-forma consolidated financial statements for |
Commenting on the results,
“We were very pleased to have a strong final quarter. We delivered Adjusted EBITDA growth of
“Post year end, we announced the sale of our Fresh Vegetables business. This sale will strengthen the financial position of the Group and increase our focus on our core activities.
“With our diversified product offering and wide geographic footprint, we believe our business is well positioned for growth. For the 2023 financial year, we are targeting Adjusted EBITDA of
“We thank all of our talented people for their dedication and significant contributions during this past year.”
Group Results – Fourth Quarter
Revenue increased
Adjusted EBITDA increased
Adjusted Net Income increased
Group Results – Full Year
Revenue decreased
Adjusted EBITDA decreased
Adjusted Net Income decreased by
Vegetables Transaction
On
_________________________
3 Like-for-like basis refers to the measure excluding the impact of foreign currency translation movements and acquisitions and divestitures. Refer to the Appendix for further detail on these impacts and the calculation of like-for-like variances. |
Selected Segmental Financial Information
|
Three Months Ended |
||||||||||||||
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
( |
||||||||||||||
|
Revenue |
|
Adjusted EBITDA |
|
Revenue |
|
Adjusted EBITDA |
||||||||
Fresh Fruit |
$ |
740,167 |
|
|
$ |
41,233 |
|
|
$ |
680,881 |
|
|
$ |
15,694 |
|
|
|
751,594 |
|
|
|
23,630 |
|
|
|
815,330 |
|
|
|
29,363 |
|
|
|
573,936 |
|
|
|
15,557 |
|
|
|
479,702 |
|
|
|
20,574 |
|
Fresh Vegetables |
|
315,082 |
|
|
|
(6,026 |
) |
|
|
296,848 |
|
|
|
(4,520 |
) |
Intersegment |
|
(24,581 |
) |
|
|
— |
|
|
|
(21,281 |
) |
|
|
— |
|
Total |
$ |
2,356,198 |
|
|
$ |
74,394 |
|
|
$ |
2,251,480 |
|
|
$ |
61,111 |
|
|
Year Ended |
||||||||||||||
|
|
|
Pro-forma |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
( |
||||||||||||||
|
Revenue |
|
Adjusted EBITDA |
|
Revenue |
|
Adjusted EBITDA |
||||||||
Fresh Fruit |
$ |
3,047,149 |
|
|
$ |
212,175 |
|
|
$ |
2,877,030 |
|
|
$ |
209,999 |
|
|
|
3,152,561 |
|
|
|
114,718 |
|
|
|
3,438,341 |
|
|
|
131,126 |
|
|
|
1,965,667 |
|
|
|
44,277 |
|
|
|
1,779,065 |
|
|
|
53,069 |
|
Fresh Vegetables |
|
1,205,902 |
|
|
|
(33,446 |
) |
|
|
1,280,594 |
|
|
|
(614 |
) |
Intersegment |
|
(142,426 |
) |
|
|
— |
|
|
|
(89,358 |
) |
|
|
— |
|
Total |
$ |
9,228,853 |
|
|
$ |
337,724 |
|
|
$ |
9,285,672 |
|
|
$ |
393,580 |
|
Fourth Quarter Commentary
Fresh Fruit
Revenue increased
Adjusted EBITDA increased significantly by
Revenue decreased
Adjusted EBITDA decreased
Revenue increased
Adjusted EBITDA decreased
Fresh Vegetables
Revenue increased
Adjusted EBITDA decreased
Full Year Commentary
Fresh Fruit
Revenue increased
Adjusted EBITDA increased
Revenue decreased
Adjusted EBITDA decreased
Revenue increased
Adjusted EBITDA decreased
Fresh Vegetables
Revenue decreased
Adjusted EBITDA decreased
Capital Expenditures
Capital expenditures for the year ended
Net Debt
Net Debt as of
Outlook and Strategic Priorities for Fiscal Year 2023 (forward-looking statement)
The operating environment in 2023 continues to bring both new opportunities and new challenges.
We are continuing to see improvements in global supply chains and signs of moderating inflation, which can have a positive impact on our business. However, we have also witnessed further weather events, such as colder weather in
Within our own business, we recently experienced a cybersecurity incident identified as ransomware. We moved quickly to contain the threat and have been working closely with leading cybersecurity experts to remediate the issue and secure our systems. We have also been cooperating with law enforcement. The incident had a limited overall impact on our operations; however, it was disruptive for our Chilean and Fresh Vegetables businesses in particular.
Overall, for full year 2023, we believe our business is well positioned for growth. While forecasting in the current environment is complex, we are targeting full year Adjusted EBITDA of
The above outlook includes non-GAAP financial measures. Please refer to the appendix of this release for an explanation and reconciliation of our historical non-GAAP financial measures used in this release to comparable GAAP financial measures.
Dividend
On
About
A global leader in fresh produce,
Webcast and Conference Call Information
The conference call can be accessed live by dialing (646) 307-1963 in the US or +353 (1) 582 2023 in
Forward-looking information
Certain statements made in this press release that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s beliefs, assumptions, and expectations of our future economic performance, considering the information currently available to management. These statements are not statements of historical fact. The words “believe,” “may,” “could,” “will,” “should,” “would,” “anticipate,” “estimate,” “expect,” “intend,” “objective,” “seek,” “strive,” “target” or similar words, or the negative of these words, identify forward-looking statements. The inclusion of this forward-looking information should not be regarded as a representation by us or any other person that the future plans, estimates, or expectations contemplated by us will be achieved. Such forward-looking statements are subject to various risks and uncertainties and assumptions relating to our operations, financial results, financial condition, business prospects, growth strategy and liquidity. Accordingly, there are, or will be, important factors that could cause our actual results to differ materially from those indicated in these statements. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, our actual results may vary materially from what we may have expressed or implied by these forward-looking statements. We caution that you should not place undue reliance on any of our forward-looking statements. Any forward-looking statement speaks only as of the date on which such statement is made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made except as required by the federal securities laws.
Appendix |
|||||||||||||||||||
Consolidated Statements of Operations - Unaudited |
|||||||||||||||||||
|
Three Months Ended |
|
Year Ended |
||||||||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|
2021 |
||||||||||
|
|
|
|
|
|
|
|
|
Pro-forma |
||||||||||
|
( |
||||||||||||||||||
Revenues, net |
$ |
2,356,198 |
|
|
$ |
2,251,480 |
|
|
$ |
9,228,853 |
|
|
$ |
6,454,402 |
|
|
$ |
9,285,672 |
|
Cost of sales4 |
|
(2,198,911 |
) |
|
|
(2,157,090 |
) |
|
|
(8,634,144 |
) |
|
|
(6,105,271 |
) |
|
|
(8,565,685 |
) |
Gross profit |
|
157,287 |
|
|
94,390 |
|
|
594,709 |
|
|
349,131 |
|
|
719,987 |
|
||||
Selling, marketing, general and administrative expenses4 |
|
(127,669 |
) |
|
|
(130,873 |
) |
|
|
(491,712 |
) |
|
|
(349,769 |
) |
|
|
(517,712 |
) |
Merger, transaction and other related costs |
|
— |
|
|
|
(1,258 |
) |
|
|
— |
|
|
|
(30,072 |
) |
|
|
— |
|
(Loss) gain on disposal of businesses |
|
(50 |
) |
|
|
606 |
|
|
|
192 |
|
|
|
11 |
|
|
|
11 |
|
Impairment of property, plant and equipment |
|
(397 |
) |
|
|
— |
|
|
|
(397 |
) |
|
|
— |
|
|
|
— |
|
Gain on asset sales |
|
2,559 |
|
|
|
319 |
|
|
|
11,634 |
|
|
|
581 |
|
|
|
3,323 |
|
Operating income (loss) |
|
31,730 |
|
|
|
(36,816 |
) |
|
|
114,426 |
|
|
|
(30,118 |
) |
|
|
205,609 |
|
Other income (expense), net |
|
(9,112 |
) |
|
|
791 |
|
|
|
11,322 |
|
|
|
8,658 |
|
|
|
20,572 |
|
Interest income |
|
2,046 |
|
|
|
2,112 |
|
|
|
6,642 |
|
|
|
3,938 |
|
|
|
5,321 |
|
Interest expense |
|
(19,761 |
) |
|
|
(12,843 |
) |
|
|
(61,485 |
) |
|
|
(27,030 |
) |
|
|
(45,520 |
) |
Income (loss) before income taxes and equity earnings |
|
4,903 |
|
|
|
(46,756 |
) |
|
|
70,905 |
|
|
|
(44,552 |
) |
|
|
185,982 |
|
Income tax benefit (expense) |
|
5,704 |
|
|
|
18,171 |
|
|
|
34,059 |
|
|
|
13,333 |
|
|
|
(32,089 |
) |
Equity method earnings |
|
2,698 |
|
|
|
4,009 |
|
|
|
6,726 |
|
|
|
48,027 |
|
|
|
23,658 |
|
Net income (loss) |
|
13,305 |
|
|
|
(24,576 |
) |
|
|
111,690 |
|
|
|
16,808 |
|
|
|
177,551 |
|
Less: Net income attributable to noncontrolling interests |
|
(6,524 |
) |
|
|
(4,675 |
) |
|
|
(25,194 |
) |
|
|
(24,027 |
) |
|
|
(25,900 |
) |
Net income (loss) attributable to |
$ |
6,781 |
|
|
$ |
(29,251 |
) |
|
$ |
86,496 |
|
|
$ |
(7,219 |
) |
|
$ |
151,651 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income (loss) per share attributable to |
$ |
0.07 |
|
|
$ |
(0.31 |
) |
|
$ |
0.91 |
|
|
$ |
(0.10 |
) |
|
$ |
1.60 |
|
Net income (loss) per share attributable to |
$ |
0.07 |
|
|
$ |
(0.31 |
) |
|
$ |
0.91 |
|
|
$ |
(0.10 |
) |
|
$ |
1.60 |
|
Weighted average shares outstanding – basic |
|
94,899 |
|
|
|
94,878 |
|
|
|
94,886 |
|
|
|
72,190 |
|
|
|
94,878 |
|
Weighted average shares outstanding – diluted |
|
94,928 |
|
|
|
95,041 |
|
|
|
94,906 |
|
|
|
72,190 |
|
|
|
95,030 |
|
4 The consolidated statement of operations for the three months ended |
Consolidated Balance Sheets - Unaudited | |||||||
|
2022 |
|
2021 |
||||
|
|
|
|
||||
ASSETS |
( |
||||||
Cash and cash equivalents |
$ |
228,840 |
|
$ |
250,561 |
||
Short-term investments |
|
5,367 |
|
|
|
6,115 |
|
Trade receivables, net of allowances for credit losses of |
|
605,154 |
|
|
|
719,114 |
|
Grower advance receivables, net of allowances of |
|
120,940 |
|
|
|
72,350 |
|
Other receivables, net of allowances of |
|
137,575 |
|
|
|
125,908 |
|
Inventories, net of allowances of |
|
436,878 |
|
|
|
410,737 |
|
Prepaid expenses |
|
55,045 |
|
|
|
45,339 |
|
Other current assets |
|
15,034 |
|
|
|
11,011 |
|
Assets held-for-sale |
|
645 |
|
|
|
200 |
|
Total current assets |
|
1,605,478 |
|
|
|
1,641,335 |
|
Long-term investments |
|
16,498 |
|
|
|
23,433 |
|
Investments in unconsolidated affiliates |
|
124,239 |
|
|
|
128,407 |
|
Actively marketed property.. |
|
31,007 |
|
|
|
50,364 |
|
Property, plant and equipment, net of accumulated depreciation of |
|
1,343,307 |
|
|
|
1,430,850 |
|
Operating lease right-of-use assets |
|
392,797 |
|
|
|
368,632 |
|
|
|
497,453 |
|
|
|
511,333 |
|
DOLE brand |
|
306,280 |
|
|
|
306,280 |
|
Other intangible assets, net of accumulated amortization of |
|
50,990 |
|
|
|
62,046 |
|
Other assets |
|
159,681 |
|
|
|
98,917 |
|
Deferred tax assets, net |
|
64,112 |
|
|
|
46,371 |
|
Total assets |
$ |
4,591,842 |
|
|
$ |
4,667,968 |
|
LIABILITIES AND EQUITY |
|
|
|
||||
Accounts payable |
$ |
729,615 |
|
|
$ |
696,766 |
|
Income taxes payable |
|
11,558 |
|
|
|
10,316 |
|
Accrued liabilities |
|
465,626 |
|
|
|
464,931 |
|
Bank overdrafts |
|
8,623 |
|
|
|
9,395 |
|
Current portion of long-term debt, net |
|
97,435 |
|
|
|
51,785 |
|
Current maturities of operating leases |
|
81,968 |
|
|
|
73,046 |
|
Payroll and other tax |
|
28,913 |
|
|
|
35,212 |
|
Contingent consideration |
|
1,791 |
|
|
|
2,958 |
|
Pension and postretirement benefits |
|
17,287 |
|
|
|
17,664 |
|
Dividends payable and other current liabilities |
|
17,698 |
|
|
|
9,078 |
|
Total current liabilities |
|
1,460,514 |
|
|
|
1,371,151 |
|
Long-term debt, net |
|
1,127,321 |
|
|
|
1,297,808 |
|
Operating leases, less current maturities |
|
320,272 |
|
|
|
305,714 |
|
Deferred tax liabilities, net |
|
143,376 |
|
|
|
145,689 |
|
Income tax payable, less current portion |
|
30,458 |
|
|
|
40,439 |
|
Contingent consideration, less current portion |
|
5,022 |
|
|
|
4,302 |
|
Pension and postretirement benefits, less current portion |
|
124,646 |
|
|
|
152,149 |
|
Other long-term liabilities |
|
61,248 |
|
|
|
105,310 |
|
Total liabilities |
$ |
3,272,857 |
|
|
$ |
3,422,562 |
|
Commitments and contingent liabilities: |
|
|
|
||||
Redeemable noncontrolling interests |
|
32,311 |
|
|
|
32,776 |
|
Stockholders’ equity: |
|
|
|
||||
Common stock — |
|
949 |
|
|
|
950 |
|
Additional paid-in capital |
|
795,063 |
|
|
|
792,223 |
|
Retained earnings |
|
469,249 |
|
|
|
413,335 |
|
Accumulated other comprehensive loss |
|
(104,133 |
) |
|
|
(125,919 |
) |
Total equity attributable to |
|
1,161,128 |
|
|
|
1,080,589 |
|
Equity attributable to noncontrolling interests |
|
125,546 |
|
|
|
132,041 |
|
Total equity |
|
1,286,674 |
|
|
|
1,212,630 |
|
Total liabilities, redeemable noncontrolling interests and equity |
$ |
4,591,842 |
|
|
$ |
4,667,968 |
|
Consolidated Statements of Cash Flows - Unaudited |
|||||||
|
Year Ended |
||||||
|
2022 |
|
2021 |
||||
|
|
|
|
||||
Operating Activities |
( |
||||||
Net income |
$ |
111,690 |
|
|
$ |
16,808 |
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
|
|
|
||||
Depreciation and amortization |
|
130,997 |
|
|
|
72,955 |
|
Incremental charges on purchase accounting valuation of biological assets and inventory |
|
41,145 |
|
|
|
65,916 |
|
Net (gain) on sale of assets and asset write-offs |
|
(11,634 |
) |
|
|
(581 |
) |
Impairment of property, plant and equipment |
|
397 |
|
|
|
— |
|
Net (gain) loss on financial instruments |
|
7,167 |
|
|
|
(3,910 |
) |
Stock-based compensation expense |
|
4,500 |
|
|
|
815 |
|
Equity method earnings |
|
(6,726 |
) |
|
|
(48,027 |
) |
Net (gain) on disposal of businesses |
|
(192 |
) |
|
|
(11 |
) |
Amortization of debt discounts and debt issuance costs |
|
6,213 |
|
|
|
2,634 |
|
Deferred tax (benefit) |
|
(35,044 |
) |
|
|
(23,168 |
) |
Pension and other postretirement benefit plan expense |
|
3,151 |
|
|
|
2,913 |
|
Dividends received from equity method investees |
|
9,817 |
|
|
|
12,137 |
|
Fair value movement on contingent consideration |
|
(14 |
) |
|
|
1,036 |
|
Other |
|
(194 |
) |
|
|
2,322 |
|
Changes in operating assets and liabilities: |
|
|
|
||||
Receivables, net of allowances |
|
19,708 |
|
|
|
(20,542 |
) |
Inventories |
|
(38,252 |
) |
|
|
(56,603 |
) |
Accrued and other current and long-term liabilities |
|
(3,837 |
) |
|
|
(8,315 |
) |
Cash flow provided by operating activities |
|
238,892 |
|
|
|
16,379 |
|
Investing Activities |
|
|
|
||||
Sales of assets |
|
36,676 |
|
|
|
26,308 |
|
Capital expenditures |
|
(97,998 |
) |
|
|
(65,438 |
) |
Acquisitions, net of cash acquired |
|
(4,886 |
) |
|
|
103,595 |
|
Proceeds from sales investment in unconsolidated affiliates |
|
421 |
|
|
|
10,607 |
|
Insurance proceeds |
|
2,278 |
|
|
|
10,455 |
|
Purchases of investments |
|
(458 |
) |
|
|
(1,210 |
) |
Investments in unconsolidated affiliates |
|
(3,450 |
) |
|
|
(1,833 |
) |
Other |
|
912 |
|
|
|
332 |
|
Cash flow provided by (used in) investing activities |
|
(66,505 |
) |
|
|
82,816 |
|
Financing Activities |
|
|
|
||||
Proceeds from borrowings and overdrafts |
|
1,293,280 |
|
|
|
2,145,427 |
|
Repayments on borrowings and overdrafts |
|
(1,411,467 |
) |
|
|
(2,487,130 |
) |
Payment of debt issuance costs |
|
(304 |
) |
|
|
(22,133 |
) |
Dividends paid to shareholders |
|
(30,364 |
) |
|
|
(17,092 |
) |
Dividends paid to noncontrolling interests |
|
(21,632 |
) |
|
|
(21,683 |
) |
Other noncontrolling interest activity, net |
|
— |
|
|
|
382 |
|
Proceeds from exercise of stock options |
|
— |
|
|
|
7,041 |
|
Payments of contingent consideration |
|
(2,909 |
) |
|
|
(5,031 |
) |
Proceeds received from issuance of common stock in initial public offering, net of issuance costs |
|
— |
|
|
|
398,876 |
|
Cash flow (used in) financing activities |
|
(173,396 |
) |
|
|
(1,343 |
) |
Effect of foreign currency exchange rate changes on cash |
|
(20,712 |
) |
|
|
(7,794 |
) |
Increase (decrease) in cash and cash equivalents |
|
(21,721 |
) |
|
|
90,058 |
|
Cash and cash equivalents at beginning of period |
|
250,561 |
|
|
|
160,503 |
|
Cash and cash equivalents at end of period |
$ |
228,840 |
|
|
$ |
250,561 |
|
Reconciliation from Net Income to Adjusted EBITDA - Unaudited
The following information is provided to give quantitative information related to items impacting comparability. Refer to the 'Non-GAAP Financial Measures' section of this document for additional detail on each item.
|
Three Months Ended |
|
Year Ended |
||||||||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|
2021 |
||||||||||
|
|
|
|
|
|
|
|
|
Pro-forma |
||||||||||
|
( |
||||||||||||||||||
Net income (Reported GAAP) |
$ |
13,305 |
|
|
$ |
(24,576 |
) |
|
$ |
111,690 |
|
|
$ |
16,808 |
|
|
$ |
177,551 |
|
Income tax (benefit) expense |
|
(5,704 |
) |
|
|
(18,171 |
) |
|
|
(34,059 |
) |
|
|
(13,333 |
) |
|
|
32,089 |
|
Interest expense |
|
19,761 |
|
|
|
12,843 |
|
|
|
61,485 |
|
|
|
27,030 |
|
|
|
45,520 |
|
Merger, transaction and other related costs |
|
— |
|
|
|
1,258 |
|
|
|
— |
|
|
|
30,072 |
|
|
|
— |
|
Mark to market (gains) losses |
|
8,868 |
|
|
|
(1,304 |
) |
|
|
3,049 |
|
|
|
(3,160 |
) |
|
|
(5,135 |
) |
(Gain) on asset sales |
|
(1,970 |
) |
|
|
— |
|
|
|
(10,316 |
) |
|
|
— |
|
|
|
177 |
|
Produce recalls |
|
— |
|
|
|
17,649 |
|
|
|
15,809 |
|
|
|
17,649 |
|
|
|
17,649 |
|
Incremental charges on biological assets and inventory related costs due to acquisition of Legacy Dole |
|
681 |
|
|
|
36,736 |
|
|
|
41,145 |
|
|
|
65,916 |
|
|
|
— |
|
Other items5, 6 |
|
1,053 |
|
|
|
5,482 |
|
|
|
(230 |
) |
|
|
(959 |
) |
|
|
(9,489 |
) |
Adjustments from equity method investments |
|
2,614 |
|
|
|
(1,866 |
) |
|
|
7,540 |
|
|
|
43,540 |
|
|
|
2,071 |
|
Adjusted EBIT (Non-GAAP) |
|
38,608 |
|
|
|
28,051 |
|
|
|
196,113 |
|
|
|
183,563 |
|
|
|
260,433 |
|
Depreciation |
|
30,525 |
|
|
|
27,235 |
|
|
|
120,104 |
|
|
|
61,551 |
|
|
|
113,276 |
|
Amortization of intangible assets |
|
2,645 |
|
|
|
3,183 |
|
|
|
10,893 |
|
|
|
11,404 |
|
|
|
11,404 |
|
Depreciation and amortization adjustments from equity method investments |
|
2,616 |
|
|
|
2,642 |
|
|
|
10,614 |
|
|
|
33,608 |
|
|
|
8,467 |
|
Adjusted EBITDA (Non-GAAP) |
$ |
74,394 |
|
|
$ |
61,111 |
|
|
$ |
337,724 |
|
|
$ |
290,126 |
|
|
$ |
393,580 |
|
5 For the three months ended |
6 For the year ended |
Reconciliation from Net Income attributable to
The following information is provided to give quantitative information related to items impacting comparability. Refer to the 'Non-GAAP Financial Measures' section of this document for additional detail on each item. Refer to the Appendix for supplementary detail.
|
Three Months Ended |
|
Year Ended |
||||||||||||||||
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|
2021 |
||||||||||
|
|
|
|
|
|
|
|
|
Pro-forma |
||||||||||
|
( |
||||||||||||||||||
Net income (loss) attributable to |
$ |
6,781 |
|
|
$ |
(29,251 |
) |
|
$ |
86,496 |
|
|
$ |
(7,219 |
) |
|
$ |
151,651 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
||||||||||
Amortization of intangible assets |
|
2,645 |
|
|
|
3,183 |
|
|
|
10,893 |
|
|
|
11,404 |
|
|
|
11,404 |
|
Merger, transaction and other related costs |
|
— |
|
|
|
1,258 |
|
|
|
— |
|
|
|
30,072 |
|
|
|
— |
|
Mark to market (gains) losses |
|
8,868 |
|
|
|
(1,304 |
) |
|
|
3,049 |
|
|
|
(3,160 |
) |
|
|
(5,135 |
) |
(Gain) loss on asset sales |
|
(1,970 |
) |
|
|
— |
|
|
|
(10,316 |
) |
|
|
— |
|
|
|
177 |
|
Produce recalls |
|
— |
|
|
|
17,649 |
|
|
|
15,809 |
|
|
|
17,649 |
|
|
|
17,649 |
|
Incremental charges on biological assets and inventory related costs due to acquisition of Legacy Dole |
|
681 |
|
|
|
36,736 |
|
|
|
41,145 |
|
|
|
65,916 |
|
|
|
— |
|
Other items7, 8 |
|
1,053 |
|
|
|
5,482 |
|
|
|
(230 |
) |
|
|
(959 |
) |
|
|
(9,489 |
) |
Adjustments from equity method investments |
|
662 |
|
|
|
476 |
|
|
|
2,580 |
|
|
|
1,179 |
|
|
|
1,038 |
|
Income tax on items above and discrete tax items |
|
(8,894 |
) |
|
|
(33,266 |
) |
|
|
(54,283 |
) |
|
|
(38,073 |
) |
|
|
(22,360 |
) |
NCI impact on items above |
|
(898 |
) |
|
|
(949 |
) |
|
|
(3,187 |
) |
|
|
(3,673 |
) |
|
|
(3,738 |
) |
Adjusted Net Income for Adjusted EPS calculation (Non-GAAP) |
$ |
8,928 |
|
|
$ |
14 |
|
|
$ |
91,956 |
|
|
$ |
73,136 |
|
|
$ |
141,197 |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted earnings per share – basic (Non-GAAP) |
$ |
0.09 |
|
|
$ |
— |
|
|
$ |
0.97 |
|
|
$ |
1.01 |
|
|
$ |
1.49 |
|
Adjusted earnings per share – diluted (Non-GAAP) |
$ |
0.09 |
|
|
$ |
— |
|
|
$ |
0.97 |
|
|
$ |
1.01 |
|
|
$ |
1.49 |
|
Weighted average shares outstanding – basic |
|
94,899 |
|
|
|
94,878 |
|
|
|
94,886 |
|
|
|
72,190 |
|
|
|
94,878 |
|
Weighted average shares outstanding – diluted |
|
94,928 |
|
|
|
95,041 |
|
|
|
94,906 |
|
|
|
72,190 |
|
|
|
95,030 |
|
7 For the three months ended |
8 For the year ended |
Supplemental Reconciliation of Prior Year Segment Results to Current Year Segment Results - Unaudited
|
Revenue for the Three Months Ended |
||||||||||||||||||
|
2021 |
|
Impact of Foreign Currency Translation |
|
Impact of Acquisitions and Divestitures |
|
Like-for-like Increase (Decrease) |
|
2022 |
||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||||
|
( |
||||||||||||||||||
Fresh Fruit |
$ |
680,881 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
59,286 |
|
|
$ |
740,167 |
|
|
|
815,330 |
|
|
|
(117,318 |
) |
|
|
(2,995 |
) |
|
|
56,577 |
|
|
|
751,594 |
|
|
|
479,702 |
|
|
|
(4,017 |
) |
|
|
— |
|
|
|
98,251 |
|
|
|
573,936 |
|
Fresh Vegetables |
|
296,848 |
|
|
|
— |
|
|
|
— |
|
|
|
18,234 |
|
|
|
315,082 |
|
Intersegment |
|
(21,281 |
) |
|
|
— |
|
|
|
— |
|
|
|
(3,300 |
) |
|
|
(24,581 |
) |
Total |
$ |
2,251,480 |
|
|
$ |
(121,335 |
) |
|
$ |
(2,995 |
) |
|
$ |
229,048 |
|
|
$ |
2,356,198 |
|
|
Adjusted EBITDA for the Three Months Ended |
||||||||||||||||||
|
2021 |
|
Impact of Foreign Currency Translation |
|
Impact of Acquisitions and Divestitures |
|
Like-for-like Increase (Decrease) |
|
2022 |
||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||||
|
( |
||||||||||||||||||
Fresh Fruit |
$ |
15,694 |
|
|
$ |
(132 |
) |
|
$ |
— |
|
|
$ |
25,671 |
|
|
$ |
41,233 |
|
|
|
29,363 |
|
|
|
(4,396 |
) |
|
|
64 |
|
|
|
(1,401 |
) |
|
|
23,630 |
|
|
|
20,574 |
|
|
|
59 |
|
|
|
(16 |
) |
|
|
(5,060 |
) |
|
|
15,557 |
|
Fresh Vegetables |
|
(4,520 |
) |
|
|
(29 |
) |
|
|
— |
|
|
|
(1,477 |
) |
|
|
(6,026 |
) |
Total |
$ |
61,111 |
|
|
$ |
(4,498 |
) |
|
$ |
48 |
|
|
$ |
17,733 |
|
|
$ |
74,394 |
|
|
Revenue for the Year Ended |
||||||||||||||||||
|
2021 Pro-forma |
|
Impact of Foreign Currency Translation |
|
Impact of Acquisitions and Divestitures |
|
Like-for-like Increase (Decrease) |
|
2022 |
||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||||
|
( |
||||||||||||||||||
Fresh Fruit |
$ |
2,877,030 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
170,119 |
|
|
$ |
3,047,149 |
|
|
|
3,438,341 |
|
|
|
(418,892 |
) |
|
|
(92,580 |
) |
|
|
225,692 |
|
|
|
3,152,561 |
|
|
|
1,779,065 |
|
|
|
(7,688 |
) |
|
|
— |
|
|
|
194,290 |
|
|
|
1,965,667 |
|
Fresh Vegetables |
|
1,280,594 |
|
|
|
— |
|
|
|
— |
|
|
|
(74,692 |
) |
|
|
1,205,902 |
|
Intersegment |
|
(89,358 |
) |
|
|
— |
|
|
|
— |
|
|
|
(53,068 |
) |
|
|
(142,426 |
) |
Total |
$ |
9,285,672 |
|
|
$ |
(426,580 |
) |
|
$ |
(92,580 |
) |
|
$ |
462,341 |
|
|
$ |
9,228,853 |
|
|
Adjusted EBITDA for the Year Ended |
||||||||||||||||||
|
2021 Pro-forma |
|
Impact of Foreign Currency Translation |
|
Impact of Acquisitions and Divestitures |
|
Like-for-like Increase (Decrease) |
|
2022 |
||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||||
|
( |
||||||||||||||||||
Fresh Fruit |
$ |
209,999 |
|
|
$ |
1,027 |
|
|
$ |
— |
|
|
$ |
1,149 |
|
|
$ |
212,175 |
|
|
|
131,126 |
|
|
|
(16,349 |
) |
|
|
(63 |
) |
|
|
4 |
|
|
|
114,718 |
|
|
|
53,069 |
|
|
|
326 |
|
|
|
(16 |
) |
|
|
(9,102 |
) |
|
|
44,277 |
|
Fresh Vegetables |
|
(614 |
) |
|
|
226 |
|
|
|
— |
|
|
|
(33,058 |
) |
|
|
(33,446 |
) |
Total |
$ |
393,580 |
|
|
$ |
(14,770 |
) |
|
$ |
(79 |
) |
|
$ |
(41,007 |
) |
|
$ |
337,724 |
|
Supplemental Reconciliation from Net Income attributable to
The following information is provided to give quantitative information related to items impacting comparability. Refer to the 'Non-GAAP Financial Measures' section of this document for additional detail on each item.
|
Three Months Ended
( |
|||||||||||||||
|
Revenues, net |
Cost of sales |
Gross profit |
Gross Margin % |
Selling, marketing, general and administration expenses |
Other operating charges9 |
Operating Income |
|||||||||
Reported (GAAP) |
$ |
2,356,198 |
(2,198,911 |
) |
157,287 |
6.7 |
% |
(127,669 |
) |
2,112 |
|
$ |
31,730 |
|
||
Amortization of intangible assets |
|
— |
|
— |
|
— |
|
|
2,645 |
|
— |
|
|
2,645 |
|
|
Merger, transaction and other related costs |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Mark to market (gains) losses |
|
— |
|
476 |
|
476 |
|
— |
|
— |
|
|
476 |
|
||
(Gain) loss on asset sales |
|
— |
|
— |
|
— |
|
— |
|
(1,970 |
) |
|
(1,970 |
) |
||
Produce recalls |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Incremental charges on biological assets and inventory from the Acquisition |
|
— |
|
681 |
|
681 |
|
— |
|
— |
|
|
681 |
|
||
Other items |
|
— |
|
(452 |
) |
(452 |
) |
— |
|
961 |
|
|
509 |
|
||
Adjustments from equity method investments |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Income tax on items above and discrete tax items |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
NCI impact on items above |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
2,356,198 |
|
(2,198,206 |
) |
157,992 |
|
6.7 |
% |
(125,024 |
) |
1,103 |
|
$ |
34,071 |
|
|
Three Months Ended
( |
|||||||||||||||
|
Revenues, net |
Cost of sales |
Gross profit |
Gross Margin % |
Selling, marketing, general and administration expenses |
Other operating charges10 |
Operating Income (Loss) |
|||||||||
Reported (GAAP) |
$ |
2,251,480 |
(2,157,090 |
) |
94,390 |
4.2 |
% |
(130,873 |
) |
(333 |
) |
$ |
(36,816 |
) |
||
Amortization of intangible assets |
|
— |
|
— |
|
— |
|
|
3,183 |
|
— |
|
|
3,183 |
|
|
Merger, transaction and other related costs |
|
— |
|
— |
|
— |
|
— |
|
1,258 |
|
|
1,258 |
|
||
Mark to market (gains) losses |
|
— |
|
3,353 |
|
3,353 |
|
— |
|
— |
|
|
3,353 |
|
||
(Gain) loss on asset sales |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Produce recalls |
|
— |
|
17,649 |
|
17,649 |
|
— |
|
— |
|
|
17,649 |
|
||
Incremental charges on biological assets and inventory from the Acquisition |
|
— |
|
36,736 |
|
36,736 |
|
— |
|
— |
|
|
36,736 |
|
||
Other items |
|
— |
|
639 |
|
639 |
|
— |
|
2,566 |
|
|
3,205 |
|
||
Adjustments from equity method investments |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Income tax on items above and discrete tax items |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
NCI impact on items above |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
2,251,480 |
|
(2,098,713 |
) |
152,767 |
|
6.8 |
% |
(127,690 |
) |
3,491 |
|
$ |
28,568 |
|
9 Other operating charges for the three months ended |
10 Other operating charges for the three months ended |
Three Months Ended
( |
||||||||||||||||
|
Other income, net |
Interest income |
Interest expense |
Income tax benefit (expense) |
Equity earnings |
Net Income |
Net income attributable to noncontrolling interests (NCI) |
|||||||||
Reported (GAAP) |
$ |
(9,112 |
) |
2,046 |
(19,761 |
) |
5,704 |
|
2,698 |
|
13,305 |
|
$ |
(6,524 |
) |
|
Amortization of intangible assets |
|
— |
|
— |
|
— |
|
— |
|
— |
|
2,645 |
|
|
— |
|
Merger, transaction and other related costs |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
Mark to market (gains) losses |
|
8,392 |
|
— |
|
— |
|
— |
|
— |
|
8,868 |
|
|
— |
|
(Gain) loss on asset sales |
|
— |
|
— |
|
— |
|
— |
|
— |
|
(1,970 |
) |
|
— |
|
Produce recalls |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
Incremental charges on biological assets and inventory from the Acquisition |
|
— |
|
— |
|
— |
|
— |
|
— |
|
681 |
|
|
— |
|
Other items |
|
— |
|
— |
|
— |
|
— |
|
544 |
|
1,053 |
|
|
— |
|
Adjustments from equity method investments |
|
— |
|
— |
|
— |
|
— |
|
662 |
|
662 |
|
|
— |
|
Income tax on items above and discrete tax items |
|
— |
|
— |
|
— |
|
(8,795 |
) |
(99 |
) |
(8,894 |
) |
|
— |
|
NCI impact on items above |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
(898 |
) |
Adjusted (Non-GAAP) |
$ |
(720 |
) |
2,046 |
|
(19,761 |
) |
(3,091 |
) |
3,805 |
|
16,350 |
|
$ |
(7,422 |
) |
|
Three Months Ended
( |
|||||||||||||||
|
Other income, net |
Interest income |
Interest expense |
Income tax benefit (expense) |
Equity earnings |
Net Income |
Net income attributable to noncontrolling interests (NCI) |
|||||||||
Reported (GAAP) |
$ |
791 |
|
2,112 |
(12,843 |
) |
18,171 |
|
4,009 |
|
(24,576 |
) |
$ |
(4,675 |
) |
|
Amortization of intangible assets |
|
— |
|
— |
|
— |
|
— |
|
— |
|
3,183 |
|
|
— |
|
Merger, transaction and other related costs |
|
— |
|
— |
|
— |
|
— |
|
— |
|
1,258 |
|
|
— |
|
Mark to market (gains) losses |
|
(4,657 |
) |
— |
|
— |
|
— |
|
— |
|
(1,304 |
) |
|
— |
|
(Gain) loss on asset sales |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
Produce recalls |
|
— |
|
— |
|
— |
|
— |
|
— |
|
17,649 |
|
|
— |
|
Incremental charges on biological assets and inventory from the Acquisition |
|
— |
|
— |
|
— |
|
— |
|
— |
|
36,736 |
|
|
— |
|
Other items |
|
— |
|
— |
|
— |
|
— |
|
2,277 |
|
5,482 |
|
|
— |
|
Adjustments from equity method investments |
|
— |
|
— |
|
— |
|
— |
|
476 |
|
476 |
|
|
— |
|
Income tax on items above and discrete tax items |
|
— |
|
— |
|
— |
|
(32,909 |
) |
(357 |
) |
(33,266 |
) |
|
— |
|
NCI impact on items above |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
(949 |
) |
Adjusted (Non-GAAP) |
$ |
(3,866 |
) |
2,112 |
|
(12,843 |
) |
(14,738 |
) |
6,405 |
|
5,638 |
|
$ |
(5,624 |
) |
|
Three Months Ended
|
|
Three Months Ended
|
||||||||||
|
( thousands, except per share amounts) |
|
( thousands, except per share amounts) |
||||||||||
|
Net income attributable to
|
Diluted net income per share |
|
Net income (loss) attributable to
|
Diluted net income (loss) per share |
||||||||
Reported (GAAP) |
$ |
6,781 |
|
$ |
0.07 |
|
$ |
(29,251 |
) |
$ |
(0.31 |
) |
|
Amortization of intangible assets |
|
2,645 |
|
|
|
|
3,183 |
|
|
||||
Merger, transaction and other related costs.. |
|
— |
|
|
|
1,258 |
|
||||||
Mark to market (gains) losses |
|
8,868 |
|
|
|
(1,304 |
) |
||||||
(Gain) loss on asset sales.. |
|
(1,970 |
) |
|
|
— |
|
||||||
Produce recalls.. |
|
— |
|
|
|
17,649 |
|
||||||
Incremental charges on biological assets and inventory from the Acquisition.. |
|
681 |
|
|
|
36,736 |
|
||||||
Other items.. |
|
1,053 |
|
|
|
5,482 |
|
||||||
Adjustments from equity method investments.. |
|
662 |
|
|
|
476 |
|
||||||
Income tax on items above and discrete tax items.. |
|
(8,894 |
) |
|
|
(33,266 |
) |
||||||
NCI impact on items above |
|
(898 |
) |
|
|
(949 |
) |
||||||
Adjusted (Non-GAAP) |
$ |
8,928 |
|
$ |
0.09 |
|
|
$ |
14 |
|
$ |
— |
|
|
|
|
|
|
|
||||||||
Weighted average shares outstanding – diluted |
|
94,928 |
|
|
|
|
95,041 |
|
|
|
Year Ended
( |
|||||||||||||||
|
Revenues, net |
Cost of sales |
Gross profit |
Gross Margin % |
Selling, marketing, general and administration expenses |
Other operating charges11 |
Operating Income |
|||||||||
Reported (GAAP) |
$ |
9,228,853 |
(8,634,144 |
) |
594,709 |
|
6.4 |
% |
(491,712 |
) |
11,429 |
|
$ |
114,426 |
|
|
Amortization of intangible assets |
|
— |
|
— |
|
— |
|
|
10,893 |
|
— |
|
|
10,893 |
|
|
Merger, transaction and other related costs |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Mark to market (gains) losses |
|
— |
|
2,848 |
|
2,848 |
|
— |
|
— |
|
|
2,848 |
|
||
(Gain) loss on asset sales |
|
— |
|
— |
|
— |
|
— |
|
(10,316 |
) |
|
(10,316 |
) |
||
Produce recalls |
|
— |
|
15,809 |
|
15,809 |
|
— |
|
— |
|
|
15,809 |
|
||
Incremental charges on biological assets and inventory from the Acquisition |
|
— |
|
41,145 |
|
41,145 |
|
— |
|
— |
|
|
41,145 |
|
||
Other items |
|
— |
|
(452 |
) |
(452 |
) |
(909 |
) |
587 |
|
|
(774 |
) |
||
Adjustments from equity method investments |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Income tax on items above and discrete tax items |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
NCI impact on items above |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
9,228,853 |
|
(8,574,794 |
) |
654,059 |
|
7.1 |
% |
(481,728 |
) |
1,700 |
|
$ |
174,031 |
|
|
Year Ended
( |
|||||||||||||||
|
Revenues, net |
Cost of sales |
Gross profit |
Gross Margin % |
Selling, marketing, general and administration expenses |
Other operating charges12 |
Operating Income |
|||||||||
Reported (GAAP) |
$ |
6,454,402 |
(6,105,271 |
) |
349,131 |
5.4 |
% |
(349,769 |
) |
(29,480 |
) |
$ |
(30,118 |
) |
||
Amortization of intangible assets |
|
— |
|
— |
|
— |
|
|
11,404 |
|
— |
|
|
11,404 |
|
|
Merger, transaction and other related costs.. |
|
— |
|
— |
|
— |
|
— |
|
30,072 |
|
|
30,072 |
|
||
Mark to market (gains) losses |
|
— |
|
1,257 |
|
1,257 |
|
— |
|
— |
|
|
1,257 |
|
||
(Gain) loss on asset sales.. |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Produce recalls.. |
|
— |
|
17,649 |
|
17,649 |
|
— |
|
— |
|
|
17,649 |
|
||
Incremental charges on biological assets and inventory from the Acquisition.. |
|
— |
|
65,916 |
|
65,916 |
|
— |
|
— |
|
|
65,916 |
|
||
Other items.. |
|
— |
|
623 |
|
623 |
|
— |
|
3,161 |
|
|
3,784 |
|
||
Adjustments from equity method investments.. |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Income tax on items above and discrete tax items.. |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
NCI impact on items above |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
||
Adjusted (Non-GAAP) |
$ |
6,454,402 |
|
(6,019,826 |
) |
434,576 |
|
6.7 |
% |
(338,365 |
) |
3,753 |
|
$ |
99,964 |
|
11 Other operating charges for the year ended |
12 Other operating charges for the year ended |
Year Ended
( |
||||||||||||||||
|
Other income, net |
Interest income |
Interest expense |
Income tax benefit (expense) |
Equity earnings |
Net Income |
Net income attributable to noncontrolling interests (NCI) |
|||||||||
Reported (GAAP) |
$ |
11,322 |
6,642 |
(61,485 |
) |
34,059 |
|
6,726 |
|
111,690 |
|
$ |
(25,194 |
) |
||
Amortization of intangible assets |
|
— |
|
— |
|
— |
|
— |
|
— |
|
10,893 |
|
|
— |
|
Merger, transaction and other related costs |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
Mark to market (gains) losses |
|
201 |
|
— |
|
— |
|
— |
|
— |
|
3,049 |
|
|
— |
|
(Gain) loss on asset sales |
|
— |
|
— |
|
— |
|
— |
|
— |
|
(10,316 |
) |
|
— |
|
Produce recalls |
|
— |
|
— |
|
— |
|
— |
|
— |
|
15,809 |
|
|
— |
|
Incremental charges on biological assets and inventory from the Acquisition |
|
— |
|
— |
|
— |
|
— |
|
— |
|
41,145 |
|
|
— |
|
Other items |
|
— |
|
— |
|
— |
|
— |
|
544 |
|
(230 |
) |
|
— |
|
Adjustments from equity method investments |
|
— |
|
— |
|
— |
|
— |
|
2,580 |
|
2,580 |
|
|
— |
|
Income tax on items above and discrete tax items |
|
— |
|
— |
|
— |
|
(53,876 |
) |
(407 |
) |
(54,283 |
) |
|
— |
|
NCI impact on items above |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
(3,187 |
) |
Adjusted (Non-GAAP) |
$ |
11,523 |
|
6,642 |
|
(61,485 |
) |
(19,817 |
) |
9,443 |
|
120,337 |
|
$ |
(28,381 |
) |
|
Year Ended
( |
|||||||||||||||
|
Other income, net |
Interest income |
Interest expense |
Income tax expense |
Equity earnings |
Net Income |
Net income attributable to noncontrolling interests (NCI) |
|||||||||
Reported (GAAP) |
$ |
8,658 |
|
3,938 |
(27,030 |
) |
13,333 |
|
48,027 |
|
16,808 |
|
$ |
(24,027 |
) |
|
Amortization of intangible assets |
|
— |
|
— |
|
— |
|
— |
|
— |
|
11,404 |
|
|
— |
|
Merger, transaction and other related costs |
|
— |
|
— |
|
— |
|
— |
|
— |
|
30,072 |
|
|
— |
|
Mark to market (gains) losses |
|
(4,417 |
) |
— |
|
— |
|
— |
|
— |
|
(3,160 |
) |
|
— |
|
(Gain) loss on asset sales |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
— |
|
Produce recalls |
|
— |
|
— |
|
— |
|
— |
|
— |
|
17,649 |
|
|
— |
|
Incremental charges on biological assets and inventory from the Acquisition |
|
— |
|
— |
|
— |
|
— |
|
— |
|
65,916 |
|
|
— |
|
Other items |
|
— |
|
— |
|
— |
|
— |
|
(4,743 |
) |
(959 |
) |
|
— |
|
Adjustments from equity method investments |
|
— |
|
— |
|
— |
|
— |
|
1,179 |
|
1,179 |
|
|
— |
|
Income tax on items above and discrete tax items |
|
— |
|
— |
|
— |
|
(39,406 |
) |
1,333 |
|
(38,073 |
) |
|
— |
|
NCI impact on items above |
|
— |
|
— |
|
— |
|
— |
|
— |
|
— |
|
|
(3,673 |
) |
Adjusted (Non-GAAP) |
$ |
4,241 |
|
3,938 |
|
(27,030 |
) |
(26,073 |
) |
45,796 |
|
100,836 |
|
$ |
(27,700 |
) |
|
Year Ended
|
|
Year Ended
|
||||||||||
|
( thousands, except per share amounts) |
|
( thousands, except per share amounts) |
||||||||||
|
Net income attributable to
|
Diluted net income per share |
|
Net income attributable to
|
Diluted net income per share |
||||||||
Reported (GAAP) |
$ |
86,496 |
|
$ |
0.91 |
|
$ |
(7,219 |
) |
$ |
(0.10 |
) |
|
Amortization of intangible assets |
|
10,893 |
|
|
|
|
11,404 |
|
|
||||
Merger, transaction and other related costs |
|
— |
|
|
|
30,072 |
|
||||||
Mark to market (gains) losses |
|
3,049 |
|
|
|
(3,160 |
) |
||||||
(Gain) loss on asset sales |
|
(10,316 |
) |
|
|
— |
|
||||||
Produce recalls |
|
15,809 |
|
|
|
17,649 |
|
||||||
Incremental charges on biological assets and inventory from the Acquisition |
|
41,145 |
|
|
|
65,916 |
|
||||||
Other items |
|
(230 |
) |
|
|
(959 |
) |
||||||
Adjustments from equity method investments |
|
2,580 |
|
|
|
1,179 |
|
||||||
Income tax on items above and discrete tax items |
|
(54,283 |
) |
|
|
(38,073 |
) |
||||||
NCI impact on items above |
|
(3,187 |
) |
|
|
(3,673 |
) |
||||||
Adjusted (Non-GAAP) |
$ |
91,956 |
|
$ |
0.97 |
|
|
$ |
73,136 |
|
$ |
1.01 |
|
|
|
|
|
|
|
||||||||
Weighted average shares outstanding – diluted |
|
94,906 |
|
|
|
|
72,190 |
|
|
Net Debt Reconciliation (Unaudited)
Net Debt is the primary measure used by management to analyze the Company’s capital structure. Net Debt is a non-GAAP financial measure, calculated as cash and cash equivalents, less current and long-term debt. It also excludes debt discounts and debt issuance costs. The calculation of Net Debt as of
|
|
|
|
||||
|
|
|
|
||||
|
( |
||||||
Cash and cash equivalents (Reported GAAP) |
$ |
228,840 |
|
|
$ |
250,561 |
|
Debt (Reported GAAP): |
|
|
|
||||
Long-term debt, net |
|
(1,127,321 |
) |
|
|
(1,297,808 |
) |
Current maturities |
|
(97,435 |
) |
|
|
(51,785 |
) |
Bank overdrafts |
|
(8,623 |
) |
|
|
(9,395 |
) |
Total debt, net |
|
(1,233,379 |
) |
|
|
(1,358,988 |
) |
Less: Debt discounts and debt issuance costs (Reported GAAP) |
|
(17,874 |
) |
|
|
(21,063 |
) |
Total gross debt |
|
(1,251,253 |
) |
|
|
(1,380,051 |
) |
Net Debt (Non-GAAP) |
$ |
(1,022,413 |
) |
|
$ |
(1,129,490 |
) |
Non-GAAP Financial Measures
Dole plc’s results are determined in accordance with
In addition to its results under
Adjusted EBIT is calculated from GAAP net income by: (1) adding the income tax expense or subtracting the income tax benefit; (2) adding interest expense; (3) adding mark to market losses or subtracting mark to market gains related to unrealized impacts from derivative instruments and foreign currency denominated borrowings, realized impacts on noncash settled foreign currency denominated borrowings, net foreign currency impacts on liquidated entities and fair value movements on contingent consideration; (4) other items which are separately stated based on materiality, which include adding merger, transaction and other related costs, adding incremental costs for produce recalls, adding or subtracting asset write-downs, net of insurance proceeds, subtracting the gain or adding the loss on the disposal of business interests, adding the incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole, adding impairment charges on property, plant and equipment, subtracting the fair value gain or adding the fair value loss on the acquisition of investments previously accounted for under the equity method, subtracting the gain or adding the loss on the sale of investments accounted for under the equity method, subtracting the gain or adding the loss on asset sales for assets held-for-sale and actively marketed property and adding restructuring charges and costs for legal matters not in the ordinary course of business; and (5) other adjustments from equity method investments, which includes the Company’s share of these items within equity method earnings.
Adjusted EBITDA is calculated from GAAP net income by: (1) adding the income tax expense or subtracting the income tax benefit; (2) adding interest expense; (3) adding depreciation charges; (4) adding amortization charges; (5) adding mark to market losses or subtracting mark to market gains related to unrealized impacts from derivative instruments and foreign currency denominated borrowings, realized impacts on noncash settled foreign currency denominated borrowings, net foreign currency impacts on liquidated entities and fair value movements on contingent consideration; (6) other items which are separately stated based on materiality, which include adding merger, transaction and other related costs, adding incremental costs for produce recalls, adding or subtracting asset write-downs, net of insurance proceeds, subtracting the gain or adding the loss on the disposal of business interests, adding the incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole, adding impairment charges on property, plant and equipment, subtracting the fair value gain or adding the fair value loss on the acquisition of investments previously accounted for under the equity method, subtracting the gain or adding the loss on the sale of investments accounted for under the equity method, subtracting the gain or adding the loss on asset sales for assets held-for-sale and actively marketed property and adding restructuring charges and costs for legal matters not in the ordinary course of business; and (7) other adjustments from equity method investments, which includes the Company’s share of these items within equity method earnings.
Adjusted Net Income is calculated from GAAP net income attributable to
Adjusted Earnings per Share is calculated from Adjusted Net Income divided by diluted weighted average number of shares in the applicable period.
Net Debt is a non-GAAP financial measure, calculated as GAAP cash and cash equivalents, less GAAP current and long-term debt. It also excludes GAAP debt discounts and debt issuance costs.
Pro-forma EBIT is calculated from pro-forma net income by adding pro-forma interest expense and adding the pro-forma income tax expense or subtracting the pro-forma income tax benefit, as well as including the following pro-forma adjustments: (1) adding mark to market losses or subtracting mark to market gains related to unrealized impacts from derivative instruments and foreign currency denominated borrowings, realized impacts on noncash settled foreign currency denominated borrowings, net foreign currency impacts on liquidated entities and fair value movements on contingent consideration; (2) other items which are separately stated based on materiality, which include adding merger, transaction and other related costs, adding incremental costs for produce recalls, adding or subtracting asset write-downs, net of insurance proceeds, subtracting the gain or adding the loss on the disposal of business interests, adding the incremental costs from the fair value uplift for biological assets and inventory related to the acquisition of Legacy Dole, adding impairment charges on property, plant and equipment, subtracting the fair value gain or adding the fair value loss on the acquisition of investments previously accounted for under the equity method, subtracting the gain or adding the loss on the sale of investments accounted for under the equity method, subtracting the gain or adding the loss on asset sales for assets held-for-sale and actively marketed property and adding restructuring charges and costs for legal matters not in the ordinary course of business; and (3) other adjustments from equity method investments, which includes the Company’s share of these items within equity method earnings.
Pro-forma Adjusted EBITDA is calculated from pro-forma EBIT by including the following pro-forma adjustments: (1) adding depreciation charges; and (2) adding amortization charges. It also includes the effect of the Company’s share of these listed items within investments accounted for under the equity method.
Pro-forma Adjusted Net Income is calculated from pro-forma net income attributable to
Pro-forma Adjusted Earnings per Share is calculated from pro-forma Adjusted Net Income divided by diluted weighted average number of shares in the applicable period.
Adjusted EBIT, pro-forma EBIT, Adjusted EBITDA, pro-forma Adjusted EBITDA, Adjusted Net Income, pro-forma Adjusted Net Income, Adjusted EPS, Net Debt and pro-forma Adjusted EPS are not measurements of
- They do not reflect Dole plc’s cash expenditures, or future requirements, for capital expenditures or contractual commitments;
- They do not reflect changes in, or cash requirements for, Dole plc’s working capital needs;
- They do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on Dole plc’s debt; and
- Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and these non-GAAP financial measures do not reflect cash requirements for such replacements.
Because of these limitations, pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS should not be considered as measures of discretionary cash available to
Further, pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS as used herein may not be calculated in a similar manner to, and are therefore not necessarily comparable with, similarly titled measures of other companies. However, we have included pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS herein because Dole plc’s management believes that pro-forma EBIT, pro-forma Adjusted EBITDA, pro-forma Adjusted Net Income, and pro-forma Adjusted EPS are useful performance measures.
Dole is not able to provide a reconciliation for projected FY'23 Adjusted EBITDA without undertaking unreasonable efforts.
Pro-forma Methodology
The methodology used to prepare the unaudited pro-forma consolidated financial statements for
1. |
|
All associated transaction costs reflected on |
|
2. |
|
Effective tax rate of |
|
3. |
|
Applying the results of the Purchase Price Allocation (“PPA”) exercise, acquisition accounting and debt refinancing to |
|
|
a. |
Q4 2021 year to date pro-forma results reflect a reduction in the depreciation charge of |
|
|
b. | The interest expense for Q4 2021 reflects the outcome of the refinancing. |
|
4. |
|
TP’s pickup of its |
|
5. |
|
EPS is calculated using shares in issue following the IPO and additional share issuances. | |
6. |
|
There is a year to date adjustment in Q4 2021 of |
Pro-forma Reconciliation (Unaudited) – for the year ended
|
TP |
|
DFC |
|
|
|
FV & Intercompany Adjustment |
|
Transaction Costs |
|
Costs |
|
Debt Adjustment |
|
Tax Adjustment |
|
Pro-forma Financial Statements |
|||||||||||
|
( |
|||||||||||||||||||||||||||
Revenues, net |
$ |
4,548,888 |
|
|
4,809,173 |
|
|
9,358,061 |
|
|
(72,389 |
) |
|
— |
|
— |
|
|
— |
|
|
— |
|
$ |
9,285,672 |
|
||
Cost of sales |
|
(4,179,155 |
) |
|
(4,537,683 |
) |
|
(8,716,838 |
) |
|
151,153 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
(8,565,685 |
) |
Gross profit |
|
369,733 |
|
|
271,490 |
|
|
641,223 |
|
|
78,764 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
719,987 |
|
Selling, marketing and general and administrative expenses |
|
(290,047 |
) |
|
(217,915 |
) |
|
(507,962 |
) |
|
— |
|
|
— |
|
|
(9,750 |
) |
|
— |
|
|
— |
|
|
|
(517,712 |
) |
Merger, transaction, and other related costs |
|
(26,719 |
) |
|
(5,214 |
) |
|
(31,933 |
) |
|
— |
|
|
31,933 |
|
|
— |
|
|
— |
|
|
— |
|
|
|
— |
|
Gain on disposal of businesses |
|
11 |
|
|
— |
|
|
11 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
11 |
|
Gain on asset sales |
|
581 |
|
|
7,372 |
|
|
7,953 |
|
|
(4,630 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
3,323 |
|
Operating income (loss) |
|
53,559 |
|
|
55,733 |
|
|
109,292 |
|
|
74,134 |
|
|
31,933 |
|
|
(9,750 |
) |
|
— |
|
|
— |
|
|
|
205,609 |
|
Other income, net |
|
1,557 |
|
|
19,015 |
|
|
20,572 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
20,572 |
|
Interest income |
|
2,594 |
|
|
2,727 |
|
|
5,321 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
5,321 |
|
Interest expense |
|
(21,912 |
) |
|
(44,790 |
) |
|
(66,702 |
) |
|
— |
|
|
— |
|
|
— |
|
|
21,182 |
|
|
— |
|
|
|
(45,520 |
) |
Income (loss) before income taxes and equity earnings |
|
35,798 |
|
|
32,685 |
|
|
68,483 |
|
|
74,134 |
|
|
31,933 |
|
|
(9,750 |
) |
|
21,182 |
|
|
— |
|
|
|
185,982 |
|
Income tax (expense) benefit |
|
(20,018 |
) |
|
(30,787 |
) |
|
(50,805 |
) |
|
— |
|
|
— |
|
|
3,066 |
|
|
(6,660 |
) |
|
22,310 |
|
|
|
(32,089 |
) |
Equity in net earnings of investments accounted for under the equity method |
|
46,317 |
|
|
1,737 |
|
|
48,054 |
|
|
(24,396 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
23,658 |
|
Net income (loss) |
|
62,097 |
|
|
3,635 |
|
|
65,732 |
|
|
49,738 |
|
|
31,933 |
|
|
(6,684 |
) |
|
14,522 |
|
|
22,310 |
|
|
|
177,551 |
|
Less: Net income attributable to noncontrolling interests |
|
(23,004 |
) |
|
(2,896 |
) |
|
(25,900 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
(25,900 |
) |
Net income (loss) attributable to |
$ |
39,093 |
|
|
739 |
|
|
39,832 |
|
|
49,738 |
|
|
31,933 |
|
|
(6,684 |
) |
|
14,522 |
|
|
22,310 |
|
|
$ |
151,651 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net income per share - basic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1.60 |
|
|||||||||
Net income per share - diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1.60 |
|
|||||||||
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Basic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
94,878 |
|
|||||||||
Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95,030 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005420/en/
Investor Contact:
joregan@totalproduce.com
+353 1 887 2794
Media Contact:
brian.bell@ogilvy.com
+353 87 2436 130
Source:
FAQ
What were Dole's financial results for 2022?
How did Dole's revenue perform compared to 2021?
What is the forecast for Dole's Adjusted EBITDA in 2023?